Stevanato Group (NYSE:STVN) announced today that it acquired a facility in Zhangjiagang, China, for a new manufacturing plant.
Piombino Dese, Italy-based Stevanato Group expects to begin renovations on the facility in the spring of 2022 as it works to expand in China with a new manufacturing hub for drug containment, drug delivery and diagnostic development.
Get the full story at our sister site, Drug Delivery Business News.